Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Equity Income: 2021-2023

Historic Equity Income for ImmunityBio (IBRX) over the last 2 years, with Sep 2023 value amounting to -$1.3 million.

  • ImmunityBio's Equity Income rose 71.84% to -$1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$11.1 million, marking a year-over-year decrease of 18.67%. This contributed to the annual value of -$7.5 million for FY2023, which is 37.65% up from last year.
  • ImmunityBio's Equity Income amounted to -$1.3 million in Q3 2023, which was up 68.28% from -$4.0 million recorded in Q2 2023.
  • In the past 5 years, ImmunityBio's Equity Income registered a high of -$197,000 during Q1 2022, and its lowest value of -$4.5 million during Q3 2022.
  • For the 3-year period, ImmunityBio's Equity Income averaged around -$2.6 million, with its median value being -$2.9 million (2022).
  • Within the past 5 years, the most significant YoY rise in ImmunityBio's Equity Income was 71.84% (2023), while the steepest drop was 1,086.29% (2023).
  • ImmunityBio's Equity Income (Quarterly) stood at -$803,000 in 2021, then tumbled by 342.59% to -$3.6 million in 2022, then soared by 71.84% to -$1.3 million in 2023.
  • Its last three reported values are -$1.3 million in Q3 2023, -$4.0 million for Q2 2023, and -$2.3 million during Q1 2023.